M&As this week: Pamplona Capital Management, Spherix, Quantum Hi-Tech China Biological
UK-based private equity company Pamplona Capital Management has agreed to acquire Parexel International Corporation by acquiring the entire outstanding shares of the company in an all-cash transaction.
The purchase consideration for the acquisition has been fixed at $88.1 per share, valuing the transaction at $5bn inclusive of net debt.
The target company is a biopharmaceutical firm based in the US and will become a privately held company following the acquisition, which is expected to be completed by this year's fourth quarter.
Spherix has reached an agreement to acquire a controlling stake in biopharmaceutical company, Hoth Therapeutics.
The acquirer company is a scientific research company also based in the US, and the acquisition is expected to increase Spherix’s shareholder value.
Quantum Hi-Tech China Biological has reached an agreement to acquire Shanghai ChemPartner, a contract research organisation.
Both companies involved in the acquisition are based in China. The acquisition is expected to be completed by the end of the year.